AstraZeneca PLC (LON:AZN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
11,794
-162 (-1.35%)
Sep 12, 2025, 5:42 PM BST
-1.35%
Market Cap182.89B
Revenue (ttm)41.24B
Net Income (ttm)6.05B
Shares Out1.55B
EPS (ttm)3.87
PE Ratio30.44
Forward PE16.35
Dividend2.36 (2.00%)
Ex-Dividend DateAug 7, 2025
Volume1,664,594
Average Volume1,760,297
Open11,930
Previous Close11,956
Day's Range11,772 - 11,986
52-Week Range9,574 - 12,404
Beta0.17
RSI53.33
Earnings DateNov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Sector Healthcare
Founded 1992
Employees 94,300
Stock Exchange London Stock Exchange
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD Financial Statements

News

AstraZeneca (AZN) Halts $271M UK Investment Amid Economic Uncertainty

AstraZeneca (AZN) Halts $271M UK Investment Amid Economic Uncertainty

1 day ago - GuruFocus

AstraZeneca's £200m blow to Labour as pharma giant scraps major investment

Hours after official figures showed output from the pharmaceuticals industry in the UK fell 4.5 per cent in July, Britain's biggest firm said the project at its research site has been 'paused'.

1 day ago - This is Money

AstraZeneca pauses £200m expansion in Cambridge

It comes after the pharmaceutical firm abandoned plans to invest £450 million in a vaccine plant in Merseyside earlier this year.

1 day ago - Evening Standard

AstraZeneca pauses £200m Cambridge investment

Its decision comes as the industry says there is a lack of government investment and as the US pressures firms to invest there.

1 day ago - BBC

AstraZeneca (AZN) Halts $271M Investment in UK Amid Uncertainty

AstraZeneca (AZN) Halts $271M Investment in UK Amid Uncertainty

1 day ago - GuruFocus

AstraZeneca (AZN) Halts Major Investment in UK Research Facility

AstraZeneca (AZN) Halts Major Investment in UK Research Facility

1 day ago - GuruFocus

AstraZeneca pauses £200mn Cambridge investment amid UK pharma uncertainty

AstraZeneca has become the latest major drugmaker to scale back investment in the United Kingdom, pausing a planned £200 million ($271 million) expansion of its Cambridge research site. The move, whic...

1 day ago - Invezz

AstraZeneca pauses £200m investment in Cambridge research site

Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceeding The drugmaker AstraZeneca has paused a planned £200m investment in its Cambridge research site, co...

1 day ago - The Guardian

Exclusive: AstraZeneca pauses $270 million investment in Britain

Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Brit...

1 day ago - Reuters

AstraZeneca (AZN) Advances Enhertu EMA Application for Broad Tumor Treatment

AstraZeneca (AZN) Advances Enhertu EMA Application for Broad Tumor Treatment

2 days ago - GuruFocus

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...

3 days ago - Reuters

AZN: New Regulations Aim to Enhance Drug Advertising Transparency

AZN: New Regulations Aim to Enhance Drug Advertising Transparency

4 days ago - GuruFocus

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

Biotech is back – and it's playing for keeps. President Donald Trump 's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments , from...

4 days ago - Benzinga

AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study

On Sunday, AstraZeneca Plc (AZN) released results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or...

5 days ago - Benzinga

AstraZeneca (AZN) Study Shows Enhanced Survival with TAGRISSO and Chemotherapy

AstraZeneca (AZN) Study Shows Enhanced Survival with TAGRISSO and Chemotherapy

6 days ago - GuruFocus

TN signs MoUs with Hinduja, AstraZeneca

Chennai: State govt represented by chief minister M K Stalin signed a memorandum of understanding (MoU) worth 7,500 crore with UK-based Hinduja Group .

7 days ago - The Times of India

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA (NASDAQ: SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match inves...

9 days ago - Benzinga

AstraZeneca, Corning And More On CNBC's 'Final Trades'

On CNBC's “ Halftime Report Final Trades ,” Jim Lebenthal , partner at Cerity Partners, named AstraZeneca PLC (NASDAQ: AZN) as his final trade . On Aug. 20, AstraZeneca released complete results from...

9 days ago - Benzinga

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

10 days ago - Reuters

Final Trades: AstraZeneca, Corning, the IBIT and the SPHD

The Investment Committee give you their top stocks to watch for the second half.

10 days ago - CNBC Television

Final Trades: AstraZeneca, Corning, the IBIT and the SPHD

The Investment Committee give you their top stocks to watch for the second half.

10 days ago - CNBC

Mineralys (MLYS) Soars 85% After AstraZeneca's Drug Trial Success

Mineralys (MLYS) Soars 85% After AstraZeneca's Drug Trial Success

11 days ago - GuruFocus